Axoft is a Cambridge, Massachusetts neurotechnology company developing implantable brain-computer interfaces (iBCIs) built on bio-inspired soft materials. Its proprietary Fleuron material is reported to be up to 10,000x softer than the polyimide used in existing brain implants, which reduces tissue scarring and lead migration and improves the stability of high-resolution neural recordings over time. The company has implanted its iBCI in 11 patients globally, including first-in-human cases at The Panama Clinic, and has published findings in Nature. Axoft combines materials science, electronics and AI-driven signal decoding to target neurological conditions such as coma, paralysis, depression, movement disorders and dementia.